OAA0305	Sequence and structure guided HIV-1 clade C trimeric immunogen design to induce neutralizing and V1V2 directed antibody responses	Oral abstract session with live Q&A	A25
OAA0306	Protective efficacy of a vaccine inducing Gag/Vif-specific CD8+ T but not CD4+ T cells against repeated intrarectal low-dose SIVmac239 challenges	Oral abstract session with live Q&A	A27
OAA0307	Co-immunization of DNA and protein in the same anatomical sites induces superior protective immune responses against SHIV challenge	Oral abstract session with live Q&A	A28
OAA0402	Contribution of monocytes and CD4 T cell subsets in maintaining viral reservoirs in SIV-infected macaques treated early after infection with antiretroviral drugs	Oral abstract session with live Q&A	A17
OAA0403	Cell proliferation contributes to the increase of genetically intact HIV over time	Oral abstract session with live Q&A	A16
OAA0404	Multiple sanctuary sites for intact and 'defective' HIV-1 in post-mortem tissues in individuals with suppressed HIV-1 replication: Implications for HIV-1 cure strategies	Oral abstract session with live Q&A	A16
OAA0405	High-throughput characterization of HIV latent reservoir demonstrates integration into genes associated with inflammation, cell cycle, and nuclear envelope assembly, enrichment in accessible chromatin, and large amounts of defective provirus	Oral abstract session with live Q&A	A16
OAA0406	The size of HIV reservoir is associated with telomere shortening and immunosenescence in early ART-treated HIV-infected children	Oral abstract session with live Q&A	A16
OAALB0101	Induction of cross-neutralizing antibodies and protection from heterologous tier-2 SHIV challenge by an mRNA-based vaccine in macaques	Oral abstract session with live Q&A	A25
OAALB0102	HIV envelope BG505 SOSIP immunization induces autologous virus and CD4 binding site-specific B cell lineage antibody precursor responses in infant rhesus macaques	Oral abstract session with live Q&A	A26